Laurent Antunes1, Sonia Frasquilho1, Marek Ostaszewski1,2, Jos Weber3, Laura Longhino4, Paul Antony2, Aidos Baumuratov2, Manuel Buttini2, Kathleen M Shannon5, Rudi Balling2, Nico J Diederich6,7. 1. Department of Pathology, Integrated Biobank of Luxembourg, Luxembourg-City, Luxembourg. 2. Department of Gastroenterology, Centre Hospitalier de Luxembourg, Luxembourg-City, Luxembourg. 3. Luxembourg Centre of Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg. 4. Department of Neurology, Centre Hospitalier de Luxembourg, Luxembourg-City, Luxembourg. 5. Department of Neurological Sciences, Rush University, Chicago, Illinois, USA. 6. Department of Gastroenterology, Centre Hospitalier de Luxembourg, Luxembourg-City, Luxembourg. diederdn@pt.lu. 7. Department of Neurology, Centre Hospitalier de Luxembourg, Luxembourg-City, Luxembourg. diederdn@pt.lu.
Abstract
BACKGROUND: The gut is proposed as a starting point of idiopathic IPD, but the presence of α-synuclein in the IPD colon mucosa is debated. OBJECTIVES: The objective of this study was to evaluate if α-synuclein in the colon mucosa can serve as a biomarker of IPD. METHODS: Immunohistochemistry was used to locate and quantify in a blinded approach α-synuclein in the mucosa from biopsies of the right and left colon in 19 IPD patients and 8 controls. RESULTS: Total α-synuclein was present in all but 1 IPD patients and in all controls; phosphorylated α-synuclein was present in all subjects. There was no intensity difference depending on disease status. Staining of total α-synuclein was stronger in the right colon (p = .04). CONCLUSIONS: Conventional immunohistochemistry α-synuclein staining in colon mucosal biopsies cannot serve as a biomarker of idiopathic PD. These findings do not contradict the assumption of disease starting in the colon, and a colon segment-specific risk for disease initiation can still be hypothesized.
BACKGROUND: The gut is proposed as a starting point of idiopathic IPD, but the presence of α-synuclein in the IPD colon mucosa is debated. OBJECTIVES: The objective of this study was to evaluate if α-synuclein in the colon mucosa can serve as a biomarker of IPD. METHODS: Immunohistochemistry was used to locate and quantify in a blinded approach α-synuclein in the mucosa from biopsies of the right and left colon in 19 IPD patients and 8 controls. RESULTS: Total α-synuclein was present in all but 1 IPD patients and in all controls; phosphorylated α-synuclein was present in all subjects. There was no intensity difference depending on disease status. Staining of total α-synuclein was stronger in the right colon (p = .04). CONCLUSIONS: Conventional immunohistochemistry α-synuclein staining in colon mucosal biopsies cannot serve as a biomarker of idiopathic PD. These findings do not contradict the assumption of disease starting in the colon, and a colon segment-specific risk for disease initiation can still be hypothesized.
Authors: J R Bedarf; F Hildebrand; L P Coelho; S Sunagawa; M Bahram; F Goeser; P Bork; U Wüllner Journal: Genome Med Date: 2017-04-28 Impact factor: 11.117
Authors: C Morén; Í González-Casacuberta; J Navarro-Otano; D Juárez-Flores; D Vilas; G Garrabou; J C Milisenda; C Pont-Sunyer; M Catalán-García; M Guitart-Mampel; E Tobías; F Cardellach; F Valldeoriola; A Iranzo; E Tolosa Journal: Parkinsons Dis Date: 2017-06-04
Authors: C Ruffmann; N Bengoa-Vergniory; I Poggiolini; D Ritchie; M T Hu; J Alegre-Abarrategui; L Parkkinen Journal: Neuropathol Appl Neurobiol Date: 2018-05-08 Impact factor: 8.090